Details for New Drug Application (NDA): 020524
✉ Email this page to a colleague
NDA 020524 describes MENTAX, which is a drug marketed by Norvium Bioscience and is included in two NDAs. Additional details are available on the MENTAX profile page.
The generic ingredient in MENTAX is butenafine hydrochloride. There are two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the butenafine hydrochloride profile page.
The generic ingredient in MENTAX is butenafine hydrochloride. There are two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the butenafine hydrochloride profile page.
Summary for 020524
| Tradename: | MENTAX |
| Applicant: | Norvium Bioscience |
| Ingredient: | butenafine hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CREAM;TOPICAL | Strength | 1% | ||||
| Approval Date: | Oct 18, 1996 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 020524
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Norvium Bioscience | MENTAX | butenafine hydrochloride | CREAM;TOPICAL | 020524-001 | Oct 18, 1996 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
